Business Context and Reporting Period
This Form 8-K Current Report was filed by Synergy CHC Corp. on June 11, 2025, with the earliest event reported on May 29, 2025. The filing details a significant capital structure transaction involving the satisfaction of debt owed to Knight Therapeutics International S.A. and the issuance of unregistered equity securities.
Key Financial Metrics
The filing focuses on a specific debt settlement and equity issuance rather than comprehensive period-over-period financial statements. Key figures include:
- Total Debt Satisfied: $12,713,858
- Cash Repayment: $10,000,000
- Early Payment Discount: $1,213,858
- Debt-to-Equity Conversion: $1,500,000
- Equity Issued: Pre-funded common stock purchase warrant for up to 428,570 shares
- Warrant Exercise Price: Nominal $0.00001 per share (pre-funded)
The filing text does not provide clear values for total revenue, net profit, operating cash flow, gross margins, total debt balance, or liquidity ratios outside of the specific transaction described.
Material Changes
The primary material change is the reduction of the company's debt load by approximately $12.7 million through a hybrid settlement. This transaction resulted in:
- A significant outflow of cash ($10 million) to settle obligations.
- A reduction in interest-bearing liabilities via the conversion of $1.5 million into equity.
- An increase in the company's share count potential through the issuance of the Pre-Funded Warrant to Knight Therapeutics International S.A.
Outlook, Risks, and Unusual Items
Unusual Items: The transaction involved a substantial early payment discount of $1,213,858, indicating a negotiated settlement favorable to the company compared to the face value of the debt.
Management Commentary: The filing states the company relied on the Section 4(a)(2) exemption from registration for the issuance of the Pre-Funded Warrant, citing it as a transaction not involving a public offering.
Risks and Contingencies: The Pre-Funded Warrant includes an automatic "cashless exercise" provision triggered by the earlier of June 11, 2026, or the closing of the company's next sale of equity securities. This creates a potential for immediate dilution upon future equity fundraising.
Investor Verification Checklist
- Verify the impact of the $10 million cash outflow on the company's current liquidity and cash reserves.
- Confirm the exact number of shares issued upon the exercise of the Pre-Funded Warrant and the resulting dilution to existing shareholders.
- Review the full text of the Pre-Funded Warrant (Exhibit 4.1) for additional covenants or restrictions.
- Assess whether the automatic cashless exercise clause could hinder future capital raising efforts.
- Check subsequent filings for any new debt obligations or equity sales that might trigger the warrant's automatic exercise.